SCHEMBL2866734

SCHEMBL2866734

COc1ccc(Cn2c(=O)c3c(N)n(-c4cc(OC)ccc4C)nc3c3cc(OC)c(OC(C)C)cc32)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.42
GAA P10253 2/20 0.42
MAPK1 P28482 2/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
KDM4E B2RXH2 1/20 0.39
PDE1A P54750 4/20 0.38
PDE1B Q01064 4/20 0.38
PDE1C Q14123 4/20 0.38
RXFP1 Q9HBX9 2/20 0.38
OPRK1 P41145 1/20 0.37
THRB P10828 3/20 0.36
LMNA P02545 2/20 0.36
P2RX3 P56373 1/20 0.36
TSHR P16473 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
HTT P42858 1/20 0.35
NPC1 O15118 1/20 0.35
USP2 O75604 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2871608 0.95 KDM4E (0.42) MAPTKMT2AMEN1KDM4EPDE1A
SCHEMBL2863040 0.93 MAPT (0.43) MAPTGAAMAPK1KMT2AMEN1
SCHEMBL2871290 0.92 MAPT (0.42) MAPTGAAMAPK1KMT2AMEN1
SCHEMBL2861122 0.90 PDE1A (0.39) MAPTGAAMAPK1KMT2AMEN1
SCHEMBL2864991 0.87 NPC1 (0.44) MAPTGAAKMT2AMEN1KDM4E
SCHEMBL2864254 0.86 PIK3R1 (0.41) GAAKMT2AKDM4EPDE1APDE1B
SCHEMBL2857641 0.85 PDE1B (0.38) MAPTGAAMAPK1KMT2AMEN1
SCHEMBL2859868 0.85 KDM4E (0.40) MAPTKDM4EPDE1APDE1BPDE1C
SCHEMBL2862709 0.85 RXFP1 (0.42) MAPTPDE1APDE1BPDE1CRXFP1
SCHEMBL2861196 0.84 MAPK1 (0.42) MAPTGAAMAPK1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 MAPT 4583/4885GAA 4868/4885MAPK1 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.